Navigation Links
Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
Date:4/17/2008

a further increases our interest in exploring the combination of ANA598 with interferon and ribavirin as well as with other experimental direct antivirals."

About ANA598

In June 2007, Anadys announced the nomination of ANA598 as a clinical development candidate. ANA598 was selected based on an optimized balance of preclinical properties, including intrinsic potency as an NS5b inhibitor, cellular activity in the hepatitis C replicon assay, oral bioavailability and early indicators of safety and tolerability. Anadys has recently completed IND enabling activities for ANA598 and pending allowance by the Food and Drug Administration, intends to initiate clinical studies of ANA598 in healthy volunteers in the second quarter of 2008. Following the healthy volunteer study, in the third quarter of 2008 Anadys plans to initiate a short-term Phase Ib study in patients infected with chronic HCV infection.

About Anadys

Anadys Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to improving patient care by developing novel medicines in the areas of hepatitis C and oncology. The Company is developing ANA598, a small-molecule, non-nucleoside inhibitor of the NS5B polymerase for the treatment of chronic hepatitis C and ANA773, an oral TLR7 agonist prodrug for cancer.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to the expected timing and planned development activities for ANA598, including future clinical trials and the belief that ANA598 has the broad potential utility to be used in combination with other anti-HCV agents, regardless of class, as well as the belief that ANA598 will be an active antiviral in HCV infected patients. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materiall
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
10. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
11. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... SPARTANBURG, South Carolina , May 29, ... and Molecular Health have announced a collaboration designed to ... support to the majority of cancer patients living in ... collaborate with Molecular Health to harness the power of ... from hundreds of thousands of patients to enable ,accrual ...
(Date:5/29/2015)... , May 29, 2015  Haemonetics Corporation (NYSE: ... , Chief Operating Officer, will present at the JMP ... on June 23 rd , 2015 at ... access Mr. Davies, presentation live via webcast at: ... (NYSE: HAE ) is a global healthcare company ...
(Date:5/29/2015)... 2015  World-renowned prostate surgeon and New York Urologist, Dr. ... of MR/Ultrasound Fusion-Guided Biopsy for detecting aggressive ... Center at Lenox Hill Hospital is the only center ... New York City . We,ve seen tremendous improvement ... The use of an MRI makes for a much more ...
Breaking Medicine Technology:New Collaboration to Dramatically Expand Therapeutic Clinical Trial Access for Cancer Patients Across the United States 2New Collaboration to Dramatically Expand Therapeutic Clinical Trial Access for Cancer Patients Across the United States 3New Collaboration to Dramatically Expand Therapeutic Clinical Trial Access for Cancer Patients Across the United States 4MR/Ultrasound Fusion-Guided Biopsy Better Able to Detect Aggressive Prostate Cancer, New Study Says 2
... FRANCISCO, Nov. 7 Epiphany Biosciences announced,today that ... 2b clinical trial with,valomaciclovir (EPB-348) for the treatment ... a highly potent anti-viral with enhanced,delivery and bioavailability. ... an important milestone in,our development of valomaciclovir," said ...
... in Watt Poultry USA states that acidic treatments benefit poultry ... ... FreshFx Antimicrobial Solution,which is used to reduce pathogens during poultry processing, ... to solve the,"yield/pathogen reduction dilemma." Citing recent studies in large-scale ...
Cached Medicine Technology:Epiphany Biosciences Reports Initiation and Enrollment in Valomaciclovir Study for Shingles 2FreshFx Recognized for use in the Scalder as a Solution to the 'Yield/Pathogen Reduction Dilemma' 2
(Date:5/30/2015)... (PRWEB) May 30, 2015 One of ... lack of local healthcare options available. Often, the ruralness ... healthcare. For those in rural areas feeling the crunch ... health insurance or tired of paying high premiums and ... connecting patients with licensed physicians via the power of ...
(Date:5/30/2015)... New York, New York (PRWEB) May 30, 2015 ... ordered to pay $100 million in punitive and ... http://www.vaginalmeshlawsuit2015.com/ ) plaintiff who suffered serious complications following ... devices. According to a verdict rendered on May ... awarded $25 million in compensatory damages after the ...
(Date:5/30/2015)... May 30, 2015 EHO offers a ... Portal that gives hospices the ability to manage their ... of this business model, EHO has been able to ... to its clients and survive among the giants of ... management systems three years ago, it has simplified the ...
(Date:5/30/2015)... Nicole Blodgett, Vice President of Secura ... designation to further her expertise in the income ... insurance advisors, health care professionals, and financial planners ... associated with the risk and the cost with ... the latest accomplishment in Nicole's journey with Secura ...
(Date:5/30/2015)... 2015 The Brain Fitness Education seminar ... ONEgeneration Senior Enrichment Center, headed by 1Heart Client Care ... and Brain Fitness Program Director Tee Barr. , Senior ... that there are many ways to enrich and further ... residents the different ways to overcome dementia and memory ...
Breaking Medicine News(10 mins):Health News:Online USA Doctors Brings Healthcare to the Masses with New E-Consults 2Health News:Online USA Doctors Brings Healthcare to the Masses with New E-Consults 3Health News:Boston Scientific Transvaginal Mesh Lawsuit Trial Ends With $100 Million Verdict 2Health News:Boston Scientific Transvaginal Mesh Lawsuit Trial Ends With $100 Million Verdict 3Health News:Boston Scientific Transvaginal Mesh Lawsuit Trial Ends With $100 Million Verdict 4Health News:Secura Consultants Expands Disability Insurance Expertise 2Health News:1Heart Caregiver Services Brings Brain Fitness Education Seminar at ONEgeneration 2Health News:1Heart Caregiver Services Brings Brain Fitness Education Seminar at ONEgeneration 3
... Informatics is hosting a meeting that is to discuss ... health records. The first meeting on Personally Controlled Health ... 10-11. // ,"The work done at this ... of healthcare information infrastructure," said keynote speaker Mitch Kapor, ...
... of four counts of misconduct. ,The doctor failed ... mother of three children. She died on February 2003 of ... constipation for more than a year. The doctor is accused ... another GP, not referring her to another specialist and failing ...
... bacteria and combinations of bacteria could explain the relationship ... to a new study published in the Journal of ... was two times higher in the ACS group for ... T. forsythia and T. denticola. Specifically, the findings suggest ...
... are concerned that children in primary schools have become ... tackle inappropriate// sexual behaviour. ,Children as young ... a rather "sexualised" manner with games such as kiss ... to set alarm bells ringing. ,Reports from ...
... enzyme found in the venom of the brown recluse spider, ... discovered a new way to open// molecular pores, called ion ... research team – Zhe Lu, MD, PhD; Yajamana Ramu, PhD; ... at Penn – screened venoms from over 100 poisonous invertebrate ...
... new vision correction technology, Zyoptix Aspheric, which reduces post-Lasik ... clinics all across India which use Zyoptix technology to ... Zyoptix Aspherix which further reduces post Lasik surgery glare, ... Director-Surgical business Rajat Goel told reporters here., ,The ...
Cached Medicine News:Health News:Meeting To Discuss Issue Of Personal Health Records 2Health News:Meeting To Discuss Issue Of Personal Health Records 3Health News:Link between Periodontal Bacteria and Heart Disease Established 2Health News:New Way to Open Cellular Ion Channels, Implications for Drug Design 2
Solarc surgical headlight is durable, comfortable, lightweight and delivers the bright, white light expected from a xenon system, but at a fraction of the cost....
Coaxial fiberoptic headlight has fixed spot size of 120mm. It weighs only 4.5 ounces....
View Mex-2 is designed for out-patient surgery, hospital rounds and house calls....
It provides excellent illumination from an inexpensive platform and is mounted on the comfortable UltraLite headband....
Medicine Products: